Evidence map›Paper›PMID 26671023›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2016

Assessing the Cumulative Contribution of New and Established Common Genetic Risk Factors to Early-Onset Prostate Cancer.

Ethan M Lange, Jessica V Ribado, Kimberly A Zuhlke, Anna M Johnson, Gregory R Keele, Jin Li, Yunfei Wang, Qing Duan, Ge Li, Zhengrong Gao and 4 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ethan M LangeDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina. elange@med.unc.edu.
Jessica V RibadoDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina.
Kimberly A ZuhlkeDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Anna M JohnsonDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Gregory R KeeleDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina.
Jin LiDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina.
Yunfei WangCenter for Translational Science, Children's National Medical Center, George Washington University, Washington, D.C.
Qing DuanDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina.
Ge LiCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina.
Zhengrong GaoCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina.
Yun LiDepartment of Genetics, University of North Carolina, Chapel Hill, North Carolina. Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina.
Jianfeng XuCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina.
S Lilly ZhengCenter for Genomics and Personalized Medicine Research, Wake Forest University, Winston-Salem, North Carolina.
Kathleen A CooneyDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan. Department of Urology, University of Michigan, Ann Arbor, Michigan.

Funding

VACCINIA PSA FOR ANDROGEN-MODULATED POST-SURGICAL RECURRENCE OF PROSTATE CANCERP50CA069568 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 1995 to 2013
$31.3M
UNC PREP in the Biomedical Sciences - Administrative SupplementR25GM089569 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROBINSON, DONITA L, RODRIGUEZ-ROMAGUERA, JOSE · 2010 to 2024
$5.6M
Genome-wide scan for genetic variants associated with early-onset prostate cancerR01CA136621 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COONEY, KATHLEEN A · 2009 to 2012
$2.4M
Design and Analysis of Sequencing-based Studies for Complex Human TraitsR01HG006292 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, YUN · 2011 to 2015
$1.8M
Imputation and Analysis of Rare Variants in Admixed PopulationsR01HG006703 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, YUN · 2012 to 2014
$931k
NCI NIH HHS P50 CA069568NCI NIH HHS R01 CA136621NHGRI NIH HHS R01 HG006292NHGRI NIH HHS R01 HG006703NIGMS NIH HHS R25 GM089569
6 · The paper itself

Abstract

backgroundWe assessed the evidence for association between 23 recently reported prostate cancer variants and early-onset prostate cancer and the aggregate value of 63 prostate cancer variants for predicting early-onset disease using 931 unrelated men diagnosed with prostate cancer prior to age 56 years and 1,126 male controls.

methodsLogistic regression models were used to test the evidence for association between the 23 new variants and early-onset prostate cancer. Weighted and unweighted sums of total risk alleles across these 23 variants and 40 established variants were constructed. Weights were based on previously reported effect size estimates. Receiver operating characteristic curves and forest plots, using defined cut-points, were constructed to assess the predictive value of the burden of risk alleles on early-onset disease.

resultsTen of the 23 new variants demonstrated evidence (P < 0.05) for association with early-onset prostate cancer, including four that were significant after multiple test correction. The aggregate burden of risk alleles across the 63 variants was predictive of early-onset prostate cancer (AUC = 0.71 using weighted sums), especially in men with a high burden of total risk alleles.

conclusionsA high burden of risk alleles is strongly associated with early-onset prostate cancer. IMPACT: Our results provide the first formal replication for several of these 23 new variants and demonstrate that a high burden of common-variant risk alleles is a major risk factor for early-onset prostate cancer. Cancer Epidemiol Biomarkers Prev; 25(5); 766-72. ©2015 AACR.

Indexed as

GenotypeHumansMaleMiddle AgedProstatic NeoplasmsRisk Factors

Identifiers

PMID26671023
PMCPMC4873425

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.